Biopharma
Biopharma Funding Levels Reach ‘New Normal’ Until Federal Interest Rates Change: PitchBook
Biopharma, Funding Levels, Federal Interest Rates, PitchBook, Venture Capital
Lilly Initiates Search for New CFO Following Anat Ashkenazi’s Departure to Alphabet
Anat Ashkenazi, CFO, Eli Lilly, Alphabet, Google, Ruth Porat, Sundar Pichai, Financial Leadership, Biopharma, Tech Industry
Biopharma Downsizing Trends 2024: Major Companies Adjusting Workforce
Biopharma, layoffs, downsizing, workforce reduction, Evotec, Lyra Therapeutics, Takeda Pharmaceuticals, industry trends, 2024
AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China
AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.
Biopharma Downsizing Trend 2024: Erasca, Bolt, Tenaya, and Other Industry Players Reduce Workforce
Biopharma, Layoffs, Downsizing, Erasca, Bolt, Tenaya, Industry Trends, Workforce Reduction, 2024
Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal
Bristol Myers, Cellares, CAR-T, biopharma, manufacturing partners, diversification, global deal
Strategic Acquisition, Partnership, and Development of Innovative Assets in Biopharma
Biopharma, Innovative Assets, Acquisition, Partnership, Development, Strategic Decision-Making, Pharmaceutical Industry, Drug Development, Market Trends, Risk Management, Portfolio Diversification
FTC’s Proposed Noncompete Ban: A Game Changer for Biopharma Job Mobility
FTC, Noncompete Ban, Biopharma Jobs, Job Mobility, Employee Rights, Competition Law
BMS-Cellares Collaboration Spotlights U.S.-China Biopharma Rivalry
BMS, Cellares, CAR-T, collaboration, U.S.-China tensions, biopharma rivalry, cell therapy, cancer treatment.